Oct 2026
Checkpoint inhibitors and chronic comedications: A retrospective study on immune-related adverse events.
In this cohort, irAE were highly prevalent and pembrolizumab-treated patients were predominant and chronic co-medications were not associated with the occurrence of irAE, however, the design of the study, short follow-up and limited sample size may have limited the detection of an effect.
Margot Vattaire-Hervé, Coralie Barbe, L. Bouazzi et al.
· Journal of Oncology Pharmacy... · 0 citations